Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q4 2024 Earnings Presentation
19 slides from Hls Therapeutics's earnings presentation, Mar 13, 2025
Slide 1: Q4 & Fiscal 2024 Conference Call
Q4 & Fiscal 2024 Conference Call March 13, 2025 Craig Millian, CEO John Hanna, CFO Brian Walsh, CCO TSX - HLS
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: A Year of Transition and Decisive Action
A Year of Transition and Decisive Action Grew Core Right-sized Strengthened New Products Spending Balance Sheet Leadership Q4 CDN product sales up 14% Reduced OpEx 10% Divested non-core assets John Hanna, CFO Vascepa profitable in Q4 Grew AEBITDA 42% ex-royalties Paid down $21M debt Brian Walsh, CCO
Slide 4: 2024: Financial Highlights
2024: Financial Highlights Revenue: 10% HLS Canadian product sales* $56.6M Adjusted EBITDA: 27% Vascepa net sales* $16.6M 1.6% Clozaril Canada net sales* Cash from operations: $8.0M 10% Operating expenses *in constant currency Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentati
Slide 5: 2025 Guidance: Return to Growth
2025 Guidance: Return to Growth Vascepa Revenue: Clozaril US Revenue: Adjusted USD $12-12.3M EBITDA: CAD $26.5-28.5M (2-4% decline) (18-26% growth) $19.5-20.5M 6-11% (17-23% growth) Growth Clozaril Canada Revenue: Royalty Revenue: CAD $35.5-36M USD $0.6-0.75M (flat) (50-60% decline) Variances to ori
Slide 6: A New Paradigm in the Treatment of Cardiovascular Risk
A New Paradigm in the Treatment of Cardiovascular Risk Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 7: Maintaining Solid Prescribing Growth
Maintaining Solid Prescribing Growth 3,500 Weekly TRx Units Since Launch 3,000 37% increase in unit demand* 2,500 2,000 1,500 29% increase 1,000 in revenue (in C$)* 500 *Q4 2024 compared to Q4 2023 0 Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, c
Slide 8: Driving Breadth & Depth
Driving Breadth & Depth 2/3 Sales force effort on existing prescribers Focus on growing depth and breadth of prescribing Consistent prescribers up 50%* 1/3 Sales force effort on high potential writers who Ave monthly prescribers up 41%* have yet to prescribe *Q4 2024 compared to Q4 2023 Bringing pri
Slide 9: Stabilizing the Payer Mix
Stabilizing the Payer Mix Enhanced physician targeting based on payer dynamics Focusing our selling efforts on gaining – and Improved retention via co-pay program retaining – new privately insured patients Simplified process for onboarding new patients Vascepa has a long patent runway into the 2030’
Slide 10: Life-changing medicine for Treatment Resistant Schizophrenia
Life-changing medicine for Treatment Resistant Schizophrenia Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 11: Strong Execution on Regional Strategies
Strong Execution on Regional Strategies Quebec: leverage West: market CSAN support for share growth patient retention through CSAN differentiation Ontario: improve Clozaril utilization amongst TRS patients *Nova Scotia strategy similar to Ontario *New Brunswick strategy similar to western provinces
Slide 12: Capital Allocation
Capital Allocation Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 13: Increased Flexibility for Capital Allocation
Increased Flexibility for Capital Allocation Share buyback announced today Solid Q4 2024 results Portfolio expansion opportunities Stronger balance sheet 1. Commercial stage assets 2. Available to license in Canada 3. Synergistic with current portfolio AEBITDA growth outlook 4. Meaningful sales pote
Slide 14: Financial Review: Solid Foundation to support our growth
Financial Review: Solid Foundation to support our growth Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 15: Q4 2024: Financial Review
Q4 2024: Financial Review Revenue: $15.5M Operating Expenses Adjusted EBITDA: $5.6M 9% 7% Excluding royalties OPEX excluding cost of sales 4% Q4’24 over Q4’23 14% Canadian product sales* 27% Selling & marketing 42% AEBITDA excluding royalties 29% Vascepa* General & admin 23% 6% Clozaril Canada* 4.5%
Slide 16: Two Products Made a Profitable Contribution to AEBITDA in Q4 2024
Two Products Made a Profitable Contribution to AEBITDA in Q4 2024 US$7.7M US$0.2M Direct contribution to Direct contribution to Adjusted EBITDA Q4 2024 Adjusted EBITDA Q4 2024 US$28.1M US($3.6)M Direct contribution to Direct contribution to Adjusted EBITDA F2024 Adjusted EBITDA F2024 Toronto Stock E
Slide 17: Strong Balance Sheet
Strong Balance Sheet Summary Balance Sheet & Capitalization De-levering the Balance Sheet (US$ millions) At Dec 31, 2023 At Dec 31, 2024 Made $21M in debt payments in 2024 Cash and Cash Equivalents 22.0 17.5 1 Debt reduction will save ~ $2M in interest expense* Senior Secured Term Loan and Revolver
Slide 18: 2024 Summary
2024 Summary 1 Grew promoted product portfolio 2 Delivered on our promise to reduce costs 3 De-levered the balance sheet and increased financial flexibility Actions set HLS up for a return to growth in 2025 Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by
Slide 19: Q4 & Fiscal 2024 Conference Call
Q4 & Fiscal 2024 Conference Call March 13, 2025 Craig Millian, CEO John Hanna, CFO Brian Walsh, CCO TSX - HLS